T. Rowe Price Associates’s CASI Pharmaceuticals CASI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-8,750
| Closed | -$104K | – | 2985 |
|
|
2021
Q3 | $104K | Sell |
8,750
-1,770
| -17% | -$21K | ﹤0.01% | 2831 |
|
|
2021
Q2 | $163K | Sell |
10,520
-5,009
| -32% | -$77.6K | ﹤0.01% | 2761 |
|
|
2021
Q1 | $373K | Buy |
15,529
+4,237
| +38% | +$102K | ﹤0.01% | 2486 |
|
|
2020
Q4 | $333K | Buy |
11,292
+3,944
| +54% | +$116K | ﹤0.01% | 2388 |
|
|
2020
Q3 | $112K | Hold |
7,348
| – | – | ﹤0.01% | 2500 |
|
|
2020
Q2 | $184K | Buy |
7,348
+50
| +0.7% | +$1.25K | ﹤0.01% | 2364 |
|
|
2020
Q1 | $149K | Hold |
7,298
| – | – | ﹤0.01% | 2363 |
|
|
2019
Q4 | $225K | Buy |
7,298
+200
| +3% | +$6.17K | ﹤0.01% | 2378 |
|
|
2019
Q3 | $237K | Buy |
7,098
+31
| +0.4% | +$1.04K | ﹤0.01% | 2352 |
|
|
2019
Q2 | $226K | Buy |
7,067
+10
| +0.1% | +$320 | ﹤0.01% | 2376 |
|
|
2019
Q1 | $203K | Buy |
7,057
+10
| +0.1% | +$288 | ﹤0.01% | 2393 |
|
|
2018
Q4 | $283K | Buy |
7,047
+2,046
| +41% | +$82.2K | ﹤0.01% | 2300 |
|
|
2018
Q3 | $234K | Buy |
5,001
+28
| +0.6% | +$1.31K | ﹤0.01% | 2411 |
|
|
2018
Q2 | $409K | Buy |
4,973
+33
| +0.7% | +$2.71K | ﹤0.01% | 2224 |
|
|
2018
Q1 | $206K | Sell |
4,940
-100
| -2% | -$4.17K | ﹤0.01% | 2394 |
|
|
2017
Q4 | $164K | Buy |
+5,040
| New | +$164K | ﹤0.01% | 2431 |
|